Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.

 

Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2018 Annual Report: Global Trends in MedTech Transactions applies the latest data to analyze current activities in the life sciences deal landscape.

In this report you can find an overview and analysis of the following medtech activities:

• Key performance indicators for the medtech market
• IPO and private financing activity and performance
• Deal activity for M&A
• A look ahead and our predictions of the future

   

 

HERE’S A SUMMARY OF KEY FINDINGS:

• Strong financing environment with capital flowing from global sources
  • Larger, later stage deals allowing companies to stay private longer as they ramp revenue
  • >20 deals above $50M, many led by cross-over investors
  • Compelling early stage investments with higher average and median Series A rounds

  Public market receptivity to MedTech IPOs

  • 8 IPOs during 2018 including Inspire Medical Systems (Obstructive Sleep Apnea), Neuronetics (Major Depressive Disorder), Axonics (Incontinence) and Electrocore (Cluster Headache and Migraine)

  Stable US FDA regulatory environment, changes in Europe

  • Tightened regulatory structure in EU may impact investment in the region as well as clinical and regulatory strategy for early stage MedTech companies
  • Reclassification of devices according to risk, contact duration and invasiveness

  Locust Walk expects enhanced M&A activity, public market receptivity to MedTech and continued investor support for innovative technologies